5 Best Clean Energy Stocks To Buy Right Now

I went out on a limb last week, and now it's time to see how that decision played out.

I predicted that Clean Energy Fuels (NASDAQ: CLNE  ) would close higher on the week. The provider of natural gas fueling solutions for transportation has been posting narrowing losses, and Wall Street was eyeing a 35% surge in revenue. The company was a solid report. Revenue came in a little light, but bottom-line results improved nicely. Shares of Clean Energy Fuels moved slightly higher on the week. I was right. I predicted that the tech-heavy Nasdaq would outperform the Dow Jones Industrial Average. (DJINDICES: ^DJI  ) . This has been a tricky call lately, so how did it play out this time? Well, the market had a strong run this week, fueled be encouraging economic news. Secondary stocks led the way, with the Nasdaq soaring 1.7% on the week. The Dow managed to close just 1% higher. I was right. My final call was for Compass Diversified Holdings (NYSE: CODI  ) to beat Wall Street's quarterly profit target. The investor in several middle-market companies has been posting blowout quarterly results over the past year, and I was banking on seeing the trend continue. Analysts were looking for a profit of $0.36 a share during the quarter, but Compass Diversified failed to beat the prognosticators. I was wrong.

Two out of three? I'll take it. That makes me eight of nine over the past three weeks.

Top Small Cap Companies To Watch For 2015: Etablissements Maurel et Prom SA (MAU)

Etablissements Maurel et Prom SA is a France-based company engaged in the exploration and production of hydrocarbons (oil and gas), and in oil drilling activities. Its main activities comprise geological surveys, seismic acquisition and processing, geophysical interpretation and drilling. The Company pursues its activities mainly in Africa and Latin America, but it also has its businesses in Gabon, Senegal, Congo, Mozambique, Syria, Tanzania, Colombia, Peru, Venezuela, France and Italy. Maurel & Prom SA operates through its direct and indirect subsidiaries, including M&P Venezuela SAS, Prestoil Kouilou, Maurel & Prom Peru Holdings, Maurel & Prom Tanzanie Ltd and Panther Eureka SRL, among others. In December, 2013, the Company the acquisition of all of the shares of Caroil SAS (excluding the South American business of Caroil) from Tuscany International Drilling Inc. and has sold all of its 109,000,000 common shares of Tuscany to an entity incorporated in the Cayman Islands. Advisors' Opinion:

• [By Riddhi Kharkia]

  Since I have touched the topic of metrics, it is worthwhile to note that Twitter�� monthly active users (MAU) number stands at 57 million as compared to approximately 1.23 billion MAUs for Facebook. Monthly active user growth ticked up just 6% for Twitter on a sequential basis, while monthly active users fell 8% year over year. Even in terms of quarterly results, Facebook was miles ahead of Twitter, which was also a factor behind the sell-off in Twitter stock.

5 Best Clean Energy Stocks To Buy Right Now: Cyberonics Inc (CYBX)

Cyberonics, Inc. (Cyberonics), incorporated in 1987, is a medical device company. The Company is engaged in the design, development, sales and marketing of implantable medical devices that provide a neuromodulation therapy, vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression (TRD) and other device solutions for the management of epilepsy.VNS Therapy System includes an implantable pulse generator to provide stimulation to the vagus nerve; a lead that connects the generator to the vagus nerve; equipment to assist with implantation surgery; equipment to assist with setting the stimulation parameters for each patient; instruction manuals, and magnets to suspend or induce stimulation manually. The VNS Therapy pulse generator and lead are surgically implanted into patients generally during an outpatient procedure. The VNS Therapy System consists of a pulse generator, a bipolar lead, a programming wand and software and a tunneling tool.

The United States Food and Drug Administration (FDA) approved the Company's VNS Therapy System in July 1997 for use as an adjunctive therapy in epilepsy patients over 12 years of age for reducing the frequency of partial onset seizures that are refractory or resistant to antiepileptic drugs. Regulatory bodies in Canada, the European Economic Area, certain countries in Eastern Europe, Russia, South America, Africa, Australia and certain countries in Asia, including Japan, China and Taiwan, have approved the VNS Therapy System for the treatment of epilepsy, many without age restrictions or seizure-type limitations. In July 2005, the FDA approved the Company's VNS Therapy System for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a depressive episode and have not had an adequate response to four or more adequate anti-depressant treatments. Regulatory bodies in the European Economic Area, Canada and Israel have approv! ed the Company's VNS Therapy System for the treatment of chronic or recurrent depression in patients who are in a treatment-resistant or treatment-intolerant depressive episode without age restrictions.

In February 2011, the Company announced FDA approval of its fifth generation generator, the AspireHC generator. In August 2011, the Company announced that the Company discovered a hardware-related design issue with the AspireHC Model 105 and AspireSR (Seizure Response) Model 106 generators. In December 2011, the FDA approved the Company's re-designed AspireHC generator, and the Company resumed its limited commercial release of the generator in the United States.

Pulse Generator

The pulse generator is an implantable, programmable signal generator designed to be coupled with the bipolar lead to deliver mild electrical pulses to the vagus nerve. The pulse generator is a battery-powered device. Before or upon depletion of the battery, the pulse generator may be removed and a new generator implanted in a short, outpatient procedure. The Model 102 (Pulse), Model 102R (Pulse Duo ), Model 103 (Demipulse), Model 104 (Demipulse Duo) and Model 105 (AspireHC), are the VNS Therapy pulse generators the Company offers and are similar in design and manufactures to a cardiac pacemaker.

Bipolar Lead

The bipolar lead conducts the electrical signal from the pulse generator to the vagus nerve. The lead incorporates electrodes, which are self-sizing, minimizing mechanical trauma to the nerve. The lead's two electrodes and anchor tether wrap around the vagus nerve, and the connector end is tunneled subcutaneously to the upper chest area, where it attaches to the pulse generator. The Company offers three lead models in the United States. The leads are available in two inner spiral diameter sizes to ensure optimal electrode placement on different-sized nerves.

Programming Wand and Software

The Company's programming wand and software are us! ed to int! errogate the implanted pulse generator and to transmit programming information from a handheld computer to the pulse generator via an inductive coupling. Programming capabilities include modification of the pulse generator's programmable parameters (pulse width, amplitude and frequency and stimulation ON and OFF intervals) and storage and retrieval of telemetry data.

Tunneling Tool

The tunneling tool is a single use, sterile, disposable surgical tool designed to be used during surgical placement of the bipolar lead. The tool is used for subcutaneous tunneling of the lead between the nerve site in the neck and the pulse generator site in the upper chest area.

Accessory Pack

The accessory pack includes two resistor assemblies used to test the function of the device prior to implantation, the bipolar lead tie-downs and one hex screwdriver. The patient kit includes two magnets, one watch-style and one pager-style.

The Company competes with Medtronic, Inc., NeuroSigma Inc. and CerboMed GmbH.

Advisors' Opinion:

• [By Benjamin Shepherd]

  The rise of public health services, improvements in sanitation and access to clean drinking water have led to a huge improvement in human life expectancy, which has jumped from only about 30 years five centuries ago to more than 75 years in most industrialized countries today.
  
  Advances in medical science have also played a major role, such as the development of antibiotics to treat once deadly infections, surgical interventions to correct once fatal injuries and medications to treat chronic conditions.
  
  We have yet to reach the limit of human ingenuity and today the trend is towards harnessing technology to break the reliance on long-term medication usage to treat chronic conditions. One area where huge strides are being made in that direction is the treatment of epilepsy.
  
  Epilepsy is the fourth most common neurological disease in the world, affecting more than 9 million people in developed countries alone, and epileptics have a mortality rate more than 25 times higher than the general population. The costs associated with dealing with the disease run in excess of $13.5 billion in the US alone.
  
  The disease is typically treated using a drug regime that includes several pills a day, including anti-convulsants and sedatives which can have unpleasant side effects. Drug therapy is typically successful in controlling seizures in about 70 percent of patients, but about a third of those who don�� respond to medication find themselves undergoing surgery to essentially remove the area of the brain triggering the seizures.
  
  Cyberonics (NSDQ: CYBX) is making headway into an alternative treatment for the disease, called vagus nerve stimulation (VNS) therapy, which can reduce the number or even eliminate the need for the drugs epileptics depend upon and requires only minor surgery.
  
  During an outpatient procedure conducted under general anesthesia, two small incisions are made, one in the upper chest area and the other in the neck. At t

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Cyberonics (Nasdaq: CYBX  ) , whose recent revenue and earnings are plotted below.

• [By Roberto Pedone]

  Another potential earnings short-squeeze candidate is implantable medical devices player Cyberonics (CYBX), which is set to release numbers on Thursday after the market close. Wall Street analysts, on average, expect Cyberonics to report revenue of $74.05 million on earnings of 55 cents per share.

  Read More: 5 Breakout Stocks Under $10 Set to Soar

  The current short interest as a percentage of the float for Cyberonics is rather high at 11.6%. That means that out of the 21.65 million shares in the tradable float, 2.52 million shares are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 4%, or by about 97,000 shares. If the bears get caught pressing their bets into a strong quarter, then shares of CYBX could easily rip sharply higher post-earnings as the shorts rush to cover some of their trades.

  From a technical perspective, CYBX is currently trending above its 50-day moving average and just below its 200-day moving average, which is neutral trendwise. This stock recently formed a double bottom chart pattern at $55.75 to $56.56 a share. Following that bottom, shares of CYBX have started to trend back above its 50-day moving average of $59.83 a share and it's quickly moving within range of triggering a near-term breakout trade above some key overhead resistance levels.

  If you're bullish on CYBX, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $63.65 to $64.08 a share with high volume. Look for volume on that move that hits near or above its three-month average action of 228,522 shares. If that breakout materializes post-earnings, then CYBX will set up to re-test or possibly take out its next major overhead resistance levels at $67.12 to $69.18 a share, or even $72 to its 52-week high at $73.52 a share.

  I would avoid CYBX or look for short-biased trades if after earnin

5 Best Clean Energy Stocks To Buy Right Now: Capstead Mortgage Corporation (CMO)

Capstead Mortgage Corporation operates as a self-managed real estate investment trust. It invests in leveraged portfolio of residential mortgage pass-through securities consisting of adjustable-rate mortgage securities issued and guaranteed by government-sponsored enterprises or by an agency of the federal government. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 1985 and is headquartered in Dallas, Texas.

Advisors' Opinion:

• [By Amanda Alix]

  Everyone got stung
  The huge drop in share price, along with the unusually heavy trading volume, smacked of investor panic. Adjustable-rate mortgage investors like Capstead (NYSE: CMO  ) , which reported earnings on Thursday, also took a dive. Even players in the 30-year mortgage market, such as American Capital Agency (NASDAQ: AGNC  ) and Annaly (NYSE: NLY  ) got dinged, right along with the ARM crowd.

• [By Rich Duprey]

  Agency mortgage real estate investment trust�Capstead Mortgage (NYSE: CMO  ) announced this morning�its second-quarter dividend of $0.31�per share, the same rate it paid last quarter.

5 Best Clean Energy Stocks To Buy Right Now: Central Fund of Canada Limited (CEF)

Central Fund of Canada is an closed-ended commodity mutual fund launched and managed by Central Group Alberta, Ltd. It invests in the commodity markets. The fund primarily invests in commodities like silver and gold. Central Fund of Canada was formed on November 15, 1961 and is domiciled in Canada.

Advisors' Opinion:

• [By Eric Parnell]

  It also remains worthwhile to hedge stock allocations to protect against any major downside event along the way. This includes positions with low correlations such as the PIMCO Total Return ETF (BOND) or the PIMCO Global Advantage Inflation Linked Bond ETF (ILB). This also includes allocations that are likely to rally sharply in the event of a stock pullback but can also continue to rise along with the market such as long-term Treasuries (TLT) or Build America Bonds (BAB). And despite the recent thrashing they have endured, the precious metals complex including gold (GLD), silver (SLV), platinum (PPLT) and palladium (PALL) continue to provide attractive long-term portfolio diversification benefits. I remain long all of these metals via the Central GoldTrust (GTU), the Central Fund of America (CEF), the Sprott Physical Silver Trust (PSLV) and the Sprott Physical Platinum and Palladium Trust (SPPP).